ANI Pharmaceuticals (NASDAQ:ANIP) Rating Reiterated by Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating reiterated by research analysts at Guggenheim in a note issued to investors on Tuesday, Benzinga reports. They presently have a $77.00 target price on the specialty pharmaceutical company’s stock. Guggenheim’s price target points to a potential upside of 17.68% from the company’s previous close.

ANIP has been the topic of several other research reports. Capital One Financial started coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They set an “overweight” rating and a $80.00 target price on the stock. HC Wainwright increased their target price on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research note on Monday, March 4th. Finally, Truist Financial increased their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, ANI Pharmaceuticals has an average rating of “Buy” and an average price target of $80.00.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $65.43 on Tuesday. ANI Pharmaceuticals has a 52 week low of $36.99 and a 52 week high of $70.81. The business’s fifty day simple moving average is $65.34 and its 200-day simple moving average is $58.75. The firm has a market cap of $1.38 billion, a PE ratio of 77.94 and a beta of 0.79. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The business had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. Equities analysts forecast that ANI Pharmaceuticals will post 3.55 earnings per share for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,787 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $65.55, for a total value of $510,437.85. Following the sale, the chief financial officer now owns 177,712 shares of the company’s stock, valued at approximately $11,649,021.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 16,809 shares of the stock in a transaction dated Friday, April 19th. The stock was sold at an average price of $65.17, for a total value of $1,095,442.53. Following the sale, the chief operating officer now owns 782,620 shares of the company’s stock, valued at approximately $51,003,345.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen P. Carey sold 7,787 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $65.55, for a total value of $510,437.85. Following the completion of the sale, the chief financial officer now directly owns 177,712 shares in the company, valued at approximately $11,649,021.60. The disclosure for this sale can be found here. Insiders have sold 156,803 shares of company stock valued at $10,363,466 in the last quarter. Corporate insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Global Alpha Capital Management Ltd. increased its holdings in shares of ANI Pharmaceuticals by 15.9% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 525,528 shares of the specialty pharmaceutical company’s stock valued at $30,512,000 after acquiring an additional 72,200 shares during the last quarter. ClariVest Asset Management LLC increased its holdings in shares of ANI Pharmaceuticals by 36.7% in the 3rd quarter. ClariVest Asset Management LLC now owns 51,338 shares of the specialty pharmaceutical company’s stock valued at $2,980,000 after acquiring an additional 13,792 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of ANI Pharmaceuticals by 287.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 146,989 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after acquiring an additional 109,015 shares during the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at about $685,000. Finally, EAM Investors LLC purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at about $1,489,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.